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CHAPTER 1
INTRODUCTION
1.1.

Staphylococcus aureus:
Staphylococcus aureus (S. aureus) are Gram positive, non-spore forming, non-

motile, facultative anaerobic bacteria. They are spherical in shape with sizes ranging
from 0.5 to 1µm in diameter. On Gram stain they appear in clusters and are positive for
coagulase and catalase production. These properties are useful in the identification of
this organism.(1)
S. aureus infections has been recognized as a major contributor to morbidity and
mortality. The organism was first identified as a pathogenic bacterium in 1880 by
Alexander Ogston of Aberdeen, Scotland. Ogston proved that these bacteria played an
important role in wound infection and subsequent septicemia. He referred to the
organism as “micrococci” in his early work and later named them “Staphylococci”, from
the Greek word staphyle, meaning bunch of grapes and kokkos meaning berry.(2, 3)
The official name ‘Staphylococcus aureus” is credited to Dr.Friedrich Julius Rosenbach,
who isolated the genus and named it “aureus” because of the golden pigment observed
on the colonies. (4)
S. aureus is an opportunistic pathogen commonly found on skin and in the upper
respiratory tracts of healthy individuals without any symptoms. When provided with
optimum opportunity this pathogen can cause a wide range of infections including minor
skin infections to fatal osteomyelitis, toxic shock syndrome, infective endocarditis and
septicemia. (5) An estimated 30% of the population are asymptomatic carriers. Its
ability to survive on dry skin and inanimate surfaces further helps spread of infection.(6,
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7) Before the discovery of antibiotics, S. aureus was responsible for 82% mortality.(8) It
remains one of the major cause of hospital and community acquired infections.(9)
The biggest challenge with the treatment of S. aureus infections is its ability to
evolve and develop resistance not only to the immune system but also to various
antibiotics, either through mutation and/or DNA transfer. Antibiotic resistance is linked to
antibiotic overuse and misuse including poor adherence to dosage regimens, selfmedication, inadequate dosing, failure to complete treatment courses, substandard
antimicrobials etc.(10)
Within a short time following the introduction of penicillin into clinical practice
there were reports of S. aureus strains already resistant to it. The incidence of infections
due to penicillin resistant strains increased rapidly from 14.1% to 59% over a period of
just two years (1946 to 1948). (11) Currently approximately 90% of S. aureus isolates
are resistant to penicillin. (12) A similar pattern followed for other classes of antibiotics
including semisynthetic penicillins (e.g. methicillin), macrolides (e.g. erythromycin),
aminoglycosides (e.g. gentamicin) and fluoroquinolones (e.g. ciprofloxacin).(13) Table 1
provides an overview of the various resistance mechanisms. In addition to antibiotic
resistance, S. aureus has developed multiple pathways to combat host defense
mechanisms including neutrophils - the main line of defense for the human immune
system. Neutrophils are recruited by chemotaxis through the release of various agents
(e.g. cytokines, IL-7) by the host cell in response to a pathogen. Neutrophils
phagocytize the pathogen and kill it by various mechanisms including formation of
superoxides. (14)

S. aureus can limit chemotaxis function to prevent neutrophil

recruitment. They are also capable of limiting superoxide function preventing digestion
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and killing of the organism. In addition to these mechanisms, S. aureus also prevent
host cells from sequestering essential nutrients such as iron, manganese, copper and
zinc, which are needed for the proper functioning of the host defense machinery. In
addition to this they also induce apoptosis in macrophages. The risk of acquiring S.
aureus infections in immunocompromised patients increases multiple fold. (15, 16)
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Table 1 Mechanism of resistance in Staphylococcus aureus
Antibiotic

Notes

Strategy of resistance

β -lactams(17)

Producing β-lactamase

Drug inactivation

mecA gene responsible for Target modification:
synthesis of a modified Decreased affinity of drug for
Penicillin Binding Protein PBP
PBP2a
Macrolide

Erm gene responsible for Target modification:
structural changes to rRNA Prevent macrolide binding
to rRNA(18)

Aminoglycosides

Modification of drug by Drug structure modification:
cellular enzymes such as Reduce affinity to ribosome
binding.(19)
aminoglycoside
acetyltransferases
or
aminoglycoside
phosphotransferases

Quinolone(20)

Mutations
the grlA and gyrA genes

in Target modification:
Mutations in the quinoloneresistance
determining
region (QRDR) reducing
drug affinity at the DNA-DNA
gyrase complex

membrane-associated
Increased drug efflux
multidrug efflux protein
(NorA) over expression
Glycopeptides(17, 21)

Synthesis
of
excess Increased wall thickness,
amounts of D-alanine-D- preventing drug to reach the
alanine
division septum the site of
action.
Acquiring VanA gene that Target modification:
replaces D-Ala-D-Ala with Reduced drug affinity to diD-Ala-D-Lac
peptide target.

5

1.2.

Treatment of Staphylococcus aureus Infection.
For treatment of S. aureus infection, the choice of drug is very important. The first

line of treatment for staphylococcal infections are β-lactam antibiotics such as nafcillin
or oxacillin. For patients with non-anaphylactic type penicillin allergies cefazolin, a first
generation cephalosporin, may be an alternative. Organisms resistant to methicillin and
its analogues are referred to as methicillin resistant S. aureus (MRSA). MRSA is a
serious problem for hospitals around the world. Serious MRSA infections are associated
with high treatment failure and mortality. According to the Centers for Disease Control
and Prevention, the invasive MRSA incidence rate in 2014 was 22.72 per 100,000
individuals, while the mortality rate of MRSA infection in 2014 was 2.88 per 100,000
individuals.(22)
For patients with anaphylactic type penicillin allergy, or if the organism is
resistant to β-lactam antibiotics (MRSA), vancomycin is considered the drug of choice.
Unfortunately, low-level vancomycin resistance is an emerging problem in hospital
settings. For patients who do not respond to vancomycin therapy alternatives such as
daptomycin is the last resort of treatment.(23)
1.2.1. β-lactams
1.2.1.1.

Mechanism of action:

β-lactam antibiotics interfere with the bacterial cell wall synthesis. They prevent
the crosslinking of the peptidoglycan layer of the cell wall. This layer is a highly crosslinked latticework structure that provides mechanical stability to the cell wall. Thus βlactams weaken the cell wall of the organism.

6

As shown in Figure 1, the bacterial cell wall is composed of repeating units of Nacetylglucosamine (NAG) [shown in blue] and N-acetylmuramic acid (NAM) [shown in
green]. Short peptide chains are attached to the NAM subunits with D-Ala-D-Ala at the
distal end. Penicillin binding proteins (PBP), also known as transpeptidase or
transamidase enzymes, bind to these peptide side chains and form a cross-link with the
expulsion of a D-Ala in the process as shown in step 2. The PBP dissociates from the
cell wall once the cross-link is formed as shown in step 3, and then is ready for reuse in
the crosslinking process. Thus a normal cell wall is formed.
In the presence of a β-lactam, the drug mimics the D-Ala-D-Ala residue of the
peptidoglycan and binds irreversibly to the active site of the PBP forming a stable
complex, as shown in step 5. The PBP is therefore unavailable for the formation of
cross-linking in the peptidoglycan layer. This disrupts the cell wall synthesis.
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Adapted from Mcstrother,
Penicillin inhibits bacterial cell
wall synthesis via suicide
inhibition

Figure 1 Mechanism of Action of β-lactam antibiotics
(1) The bacterial cell-wall before cross-linking. (2) Formation of cross-link with the
expulsion of one D-Alanine from one peptide side chain. (3) The PBP dissociates from
the wall once the cross-link has been formed. (4) β-lactam enters the active site of the
PBP (5) The β-lactam irreversibly binds to PBP and permanently blocks the active site.
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1.2.1.2.

Resistance to β-lactams

S. aureus resistance to β-lactams occurs by two main mechanisms. The
organism produces an extracellular enzyme called β-lactamase, which cleaves the βlactam ring through hydrolysis and inactivates the drug. The blaZ gene is believed to be
the gene responsible for the production of β-lactamase.(24)
The second mechanism, which is of greater concern, is the acquisition of the
mecA gene which encodes a modified PBP named PBP2a. This PBP has low affinity to
β-lactam antibiotics but can efficiently participate in cell wall synthesis.(17) This is the
main mechanism by which an organism becomes resistant to methicillin and its
analogues (MRSA).
1.2.2. Vancomycin
1.2.2.1.

Mechanism of action:

Vancomycin(VAN)

interferes

with

cell

wall

synthesis

by inhibiting

the

transpeptidation reaction. It renders the cell wall unstable and the organism becomes
prone to lysis.

However, the mechanism of inhibiting transpeptidation is entirely

different from that employed by β-lactams. Instead of binding to the PBP VAN binds to
the substrate of the transpeptidation reaction (i.e. C-terminal D -ala-D -ala end of the
peptide). VAN forms a stable non-covalent complex involving a number of hydrogen
bonds between VAN and D -ala-D -ala residue in the precursor, making it unavailable
for cell wall synthesis. The result is inhibition of cell wall synthesis and lysis of the
organism.(25)
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VAN is a large and bulky glycopeptide, therefore it cannot penetrate to the
cytoplasm. The interaction with the target i.e. D-ala-D-ala terminus of the precursor
peptide takes place only on the peptides that have been translocated to the outer
surface of the cytoplasmic membrane and where new cell wall is being synthesized.
Therefore, for VAN to be effective it should interact with the lipid linked precursors at the
site of cell wall synthesis, (i.e. at the division septum for S. aureus). (26, 27)
The mechanism of action is shown in Figure 2. In step 1 the peptidoglycan
precursors have been synthesized but not yet cross-linked. VAN binds to the D-ala-Dala residue of the peptidoglycan as shown in step 2 forming stable non-covalent bonds.
Therefore, the peptide chains are not available to the PBP for cross-linking as shown in
step 3. Thus the cell wall falls apart (step 4)

Adapted from Mcstrother, Action of vancomycin and resistance via alteration of peptide side-chains.
Figure 2 Vancomycin mechanism of action

(1)

(2)
(3)
(4)

Lipid linked precursor at the site of cell wall synthesis before cross-linking.
VAN binds to the two D-ala residues on the end of the peptide chains.
VAN bound to the peptide chains prevents them from interacting properly with the
cell wall cross-linking enzyme (PBP).
Cell wall falls apart
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1.2.2.2.

Resistance to vancomycin:

There are a number of methods and terminologies used to define vancomycin
resistance. With respect to the VAN minimum inhibitory concentrations (MIC) the
organism is said to be susceptible if its MIC is ≤ 2 mg/l (VSSA). If the VAN MIC is ≥16
mg/l they are called VAN resistant S. aureus (VRSA). S. aureus becomes resistant to
VAN by acquisition of the vanA gene from enterococci. The organism synthesizes a
modified peptidoglycan precursor D-ala-D-lac instead of D-ala-D-ala. This reduces the
affinity of VAN to the dipeptide substantially while retaining the activity of PBP.
Therefore the crosslinking can occur without any hindrance from the drug.(28) This is
shown in Figure 3.

Adapted from Mcstrother, Action of vancomycin and

resistance via alteration of peptide side-chains.
Figure 3 Vancomycin Resistant S. aureus.

(1)

(2)
(3)
(4)

Lipid linked precursor at the site of cell wall synthesis before cross-linking.
VAN cannot bind to the D-ala-D-lac side chain.
Cell wall cross-linking enzyme (PBP) successfully cross-links the peptide chain.
Stable cell wall is formed.
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It is not very common for an organism to become VRSA. More common and
concerning is the development of low-level VAN resistance (LLVR). There are two types
of LLVR including VAN intermediate S. aureus (VISA), defined as VAN MIC values
between 4 and 16 mg/l and heterogeneous VAN intermediate S. aureus (hVISA), which
have MIC values in the susceptible range but contain a sub-population that are in the
intermediate range. Since hVISA have MIC values in the normal range, they can only be
identified by population analysis.(29, 30) LLVR has been documented to have a major
impact on clinical outcomes. Higher treatment failure and persistence of infection has
been associated with both VISA and hVISA as compared to VAN susceptible S. aureus.
(31)
There are multiple pathways and genes by which S. aureus can gain intermediate
resistance to VAN.(32) A link has been found between the Accessory Gene Regulator
(agr) locus and reduced VAN susceptibility. Agr is a global regulator gene affecting the
production of various S. aureus virulence factors. Organisms with a dysfunctional agr II
locus are more prone to becoming resistant to VAN.(33). Mutations in vraAR, graSR or
walKR operons, singly or in combination, lead to modification of their respective
regulons. This results in increased thickness of the cell wall due to up regulation of cell
wall synthesis or decreased autolysis or both. There is also an increase in capsule
expression. The upregulation of the dlt operon leads to an increase in alanylation of
teichoic acid, giving a net positive charge to the cell wall. All of these changes interfere
with the interaction of drugs with the target.(34)
The increase in cell wall thickness and increase in D-ala-D-ala containing
muropeptides (false binding sites) in the cell wall leads to a reduction in the amount of
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drug reaching the division septum (site of cell wall synthesis) and therefore a reduction
in activity of the drug. This is shown in Figure 4.

Figure 4 Reduced vancomycin activity in VISA

VAN gets trapped in outer layers by binding to muropeptides. Therefore, the drug is unable to
reach the site of cell wall synthesis.
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1.2.3. Daptomycin
1.2.3.1.

Mechanism of action:

For patients who do not respond to VAN therapy, daptomycin (DAP) is used as a
last resort. It is a cyclic lipopeptide with a calcium dependent mechanism. The exact
mechanism by which DAP causes cell death is not fully understood.
The current hypothesis is that DAP exerts its effect on the target cell by primarily
disrupting membrane functions. DAP is anionic in charge by itself. When it comes in
contact with calcium in blood it becomes cationic. This facilitates its penetration into cell
membranes. The functional integrity of the membrane is disrupted and the membrane
depolarizes, triggering the leakage of potassium ions and ultimately cell death.(35, 36)

Adapted from KL Tedesco, MJ Rybak: Daptomycin, Pharmacotherapy: The Journal of
Human Pharmacology and Drug Therapy, Volume 24, Issue 1, pages 41–57, January
2004

Figure 5 Mechanism of action of Daptomycin(36)
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1.2.3.2.

Resistance to Daptomycin

The mechanism of resistance to DAP is not completely understood. When an
organism becomes resistant to DAP changes in both cell wall and membrane take
place. The resultant changes to the membrane reduces depolarization secondary to
DAP binding, which results in a loss of its antibacterial effect.
In addition, changes in the cell wall including increased thickness and an
increased positive charge of the cell membrane due to over expression of the dlt operon
contribute to DAP resistance.(37) Figure 6 shows DAP molecules repelled from the cell
wall that is positively charged.

Figure 6 Positive charged daptomycin-calcium complex repelled by the positive charged cell wall.
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DAP is often used as second line therapy and often after VAN has failed. DAP
non-susceptibility is a rising concern in health care. Many studies have shown a positive
correlation between prior low-level VAN resistance and DAP resistance.(38-40) The
changes that occur in a cell wall as it becomes resistant to VAN, like a thickened cell
wall, enhanced cell wall turnover, etc. interfere with the antimicrobial action of DAP. (40)
It has been demonstrated that there is a correlation between cell wall thickness and the
DAP MIC. In fact, a positive correlation between VAN and DAP MIC has also been
reported. Consequently, as an organism develops intermediate resistant to VAN, it is
more prone to DAP treatment failure. (41, 42)
It is interesting to note that VAN resistance acquired through acquisition of Van-A
does not affect DAP susceptibility. (43)
Regardless, alternatives to VAN for the treatment of S. aureus are needed.
1.3.

Synergy between vancomycin and β-lactam.
A β-lactam in combination with VAN has been demonstrated to be synergistic.

Many in vitro studies demonstrate synergistic activity of the combination against most S.
aureus strains. (44-47) Animal models have also corroborated the data.(48, 49)
The exact mechanism of synergy is not known but there are many hypotheses for the
synergy.
One of the theories is that the synergy is due to substrate specificity of PBP 2a.
In the presence of β-lactams all the cross-linking in the cell wall is carried out by PBP
2a. PBP 2a is able to carry out the cross-linking reaction only in monomeric
disaccharide pentapeptides. VAN competes for these monomeric disaccharide
pentapeptides. They therefore interfere with the cell wall synthesis, reducing β-lactam
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resistance. This would lead to better activity with the combination.(47, 48) The reduction
in β-lactam resistance with vancomycin use is also described as the seesaw effect. (42)
Another mechanism, though less common, is that the stress caused by the
addition of VAN to a β-lactam can cause deletion of mecA in some strains. This will
result in disruption of production of PBP2a, which is the product of mecA, leading to the
organism becoming susceptible to β-lactam antibiotics. (50, 51)
A newer concept for synergy is due to PrsA, an auxiliary factor in oxacillin
resistance. It is a chaperone protein responsible for posttranslocational folding at the
outer surface of the cytoplasmic membrane. PrsA is responsible for folding and
stabilization of PBPs. Any disruption in PrsA will lead to disruption in PBP 2a, which will
decrease β-lactam resistance.(52) The working hypothesis is that VAN pressure
disrupts PrsA, which can lead to a decrease in oxacillin MIC.
1.4.

Cefazolin (β-lactam of choice)
Cefazolin (CFZ) is a first generation cephalosporin antibiotic. It has been

documented that CFZ shows better synergy than most other β-lactam antibiotics with
VAN.(45) CFZ has a non-selective PBP profile and therefore binds to all PBPs including
PBP1, an important protein in cell division and septum formation. (53) Thus it will
interfere with cell wall repair. In addition, CFZ is a safer drug as compared to other βlactams such as nafcillin and oxacillin, having markedly fewer side effects.(54) Lastly,
the drug has a comparatively long half-life of almost 1.8 hours. The dosing interval is 8
hours making it a convenient drug to use in clinical practice.
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CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS
Development of resistance in S. aureus has been a big concern in the treatment
of infections caused by the organism. The line of therapy used today has a
disadvantage of slowly developing cross-resistance for antibiotics such as DAP
secondary to prior VAN exposure. Therefore, alternative therapy is needed to prevent
the emergence of VAN resistance and cross-resistance to other antibiotics. The primary
aim of this experiment is first: to prove that sub-optimal VAN exposure in S. aureus will
lead to development of VISA. Secondly, VAN in combination with CFZ will prevent the
development of VISA, regardless of sub-therapeutic VAN exposure. In addition to this
we will evaluate if the combination of VAN plus CFZ is synergistic against various
phenotypes of MRSA.
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CHAPTER 3
MATERIALS AND METHODS
3.1

Materials

3.1.1 Bacterial Strains
Two S. aureus strains were selected for the studies for the development and
prevention of resistance to VAN in presence of CFZ. The strains chosen were RN9120,
which is a MSSA with dysfunctional agr- II (knockout) and JH1, which is a well
described clinical MRSA strain. Both of these strains have been extensively studied in
the literature and have a proclivity to gain resistance to VAN and become VISA upon
VAN exposure.(33, 55-58).
An additional 10 MRSA isolates of different drug resistant phenotypes including
MRSA, hVISA, VISA and linezolid-resistant S. aureus (LZD-R) were selected for time
kill studies to demonstrate synergy with the combination of VAN and CFZ in different
phenotypes of S. aureus. The organisms selected are given in Table 2.
Table 2 Microorganisms selected for time kill studies

MRSA

hVISA

VISA

LZD-R

494

6911

3219

6499

8845

6837

2325

6256

3651
6387
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Kocuria rhizophila ATCC 9341 was the indicator organism used for bioassays to
verify

VAN

concentrations

and

24

hour

exposures

in

the

in-vitro

pharmacokinetic/pharmacodynamic (PK/PD) models.
3.1.2 Media
Mueller Hinton Broth (MHB, Difco, Detroit, MI), was used for susceptibility testing,
in-vitro one-compartment PK/PD models and time kill assays. Tryptic soy agar (TSA,
Difco, Detroit, MI) was used for S. aureus culturing, growth and colony enumeration.
Brain heart infusion agar (BHIA, Difco, Detroit, MI), a highly nutritious media,
supplement with VAN was used for resistance screening and population analysis.
Antibiotic assay medium 1 agar (AA1) was used for determination of VAN
concentrations from in-vitro PK/PD models.
3.1.3 Antimicrobials
VAN, the primary drug for the studies, was purchased commercially from Pfizer,
New York City, NY. The β-lactams; CFZ was purchased commercially from Sandoz,
Princeton, NJ and oxacillin (OXA) was purchased from Sigma Aldrich, St Louis, MO.
Teicoplanin (TEI) a glycopeptide used for susceptibility testing was purchased
commercially from Sanofi Aventis, Bridgewater, NJ. DAP a lipopeptide used for
susceptibility testing was purchased commercially from Merck Pharmaceuticals,
Lexington, MA.
3.2

Methods
Susceptibility testing was carried out for each antibiotic alone and in combination.

Minimum inhibitory concentration (MIC) for all S. aureus isolates was determined using
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broth dilution method or Epsilometer test (Etest). Methods used to generate a VISA
from a VAN susceptible organism included a gradient plate method and serial passage.
A one compartment in-vitro PK/PD model was used to simulate human PK of each
antimicrobial agent including VAN and CFZ. The pharmacokinetics for VAN were
determined by bioassay.
The organisms obtained at the end of the PK/PD models were tested for changes
in MIC to the various antibiotics. If a change in MIC was observed, population analysis
(PAP) was completed to determine if a shift in population occurred. In addition to this
passage, studies using antibiotic free media were done to study if the mutant obtained
was stable.
In the second part of this investigation, time kill studies were carried out using
VAN alone and in combination with CFZ. The experiments evaluated the bactericidal
nature of the antibiotics and provided data on whether the combination met the
definition of synergy.
3.2.1 Susceptibility testing
Susceptibility testing for initial profiling of the organisms was completed by Etest.
For all other susceptibility testing the microbroth dilution method was used.
Etest: In the E-test method of antimicrobial susceptibility testing antibiotic containing
strips (Estrips) are placed onto Mueller-Hinton agar(MHA) plates inoculated with known
bacterial density. For our study the bacterial suspension of 0.5 McFarland for S. aureus
was used containing about 108 CFU/ml. The sample is incubated at 35○C for 24 hr.
During the incubation period, the antimicrobial agents diffuse from their respective
antibiotic impregnated strips into the surrounding agar and producing an elliptical zone
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of growth inhibition. The MIC is determined at the point on the scale where the ellipse of
organism growth inhibition intercepts the strip.
For the oxacillin(OXA) Etest MHA agar was supplemented with 2% sodium
chloride as suggested by clinical laboratories standard institute (CLSI) guidelines. VAN
and the OXA Etest was performed for RN9120 and JH1.
Microbroth dilution method: Microbroth dilution (MBD) method for susceptibility
testing is the gold standard for determining S. aureus resistance to VAN according to
Clinical Laboratory and Standards Institute (CLSI) guidelines. The disc diffusion method
is unable to differentiate between VSSA, VISA and VRSA isolates. The bacterial
concentration used for MBD was about 106 CFU/ml. All studies were done in duplicate
to ensure reproducibility of results. MHB was used for all other drugs except oxacillin.
2% NaCl supplemented MHB was used for OXA MBD susceptibility testing. Evaluation
of MIC was done after incubation for 24 hr for VAN and OXA at 35±2○C. For all other
drugs in question the samples were read after an incubation period of 16-20 hr.
Thus this method was used to determine the initial MIC of the organism to
different drugs under consideration such as VAN, CFZ, OXA, DAP and TEI. In addition,
MBD was used to evaluate the change in MIC as a consequence to exposure to
suboptimal exposure of VAN.
3.2.2 Gradient plate serial passage
The Gradient plate method was evaluated to induce resistance using JH1. The
method involves consecutively pouring two layers of agar onto a Petri dish. For the
bottom layer 25ml of plain BHIA poured over a propped up plate to form a wedge. When
the agar solidifies the Petri dish is placed in a horizontal position and another 25ml of
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BHIA containing VAN at different concentrations being tested is poured over the wedge.
The representation of plate is shown in Figure 7. A 0.5 McFarland suspension was
made for the S. aureus being tested. The organism was streaked on the plate with a
swab from the area of lowest to highest antibiotic concentration. The plates were
incubated for 48 hours at 35±2○C. The colonies growing towards the highest antibiotic
concentration were taken and tested for MIC. They were also transferred and streaked
on plate with higher antibiotic concentration and the process was repeated. The
antibiotic used for the study was VAN and the concentration used in the plates were 2
µg/ml, 8 µg/ml, 16 µg/ml and 24 µg/ml. The MIC testing was done to see if any change
in susceptibility to VAN occurred on VAN exposure.

Figure 7 Gradient Vancomycin agar plate

3.2.3 Broth serial passage
A S. aureus suspension containing~106 CFU/ml of the organisms being tested in
BHI containing 25µg/ml VAN was made. The culture was incubated in a shaker
incubator at 35±2○C till they showed visual turbidity. Cultures showing visual turbidity
were centrifuged and the pellet was re-suspended in saline to get a 0.5 McFarland
suspension. 1:100 dilution of the bacterial suspension was done fresh BHI containing
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elevated concentration of VAN to get a 106 CFU/ml and returned to shaker incubator.
Samples showing visual growth were used to inoculate the next day’s passage, and the
concentration of VAN shall be increased stepwise WITH

0.25µg/ml increments in

concentration of VAN was made till growth was observed in 2µg/ml broth. Later
0.5µg/ml in VAN concentration increment was made till growth in 8µg/ml is observed.
The experiment was performed in duplicate. The MIC was checked every 7 days or on
from the growth in 4µg/ml VAN broth and every 2µg/ml increment higher.
The experiment was also carried out for VAN in presence on β-lactam at ½ MIC
and ¼ MIC.
3.2.4 In vitro one-compartment PK/PD Models
In vitro one-compartment PK/PD model of 250-ml capacity having inflow and
outflow ports was used. The apparatus was prefilled with medium, and VAN was
administered as boluses over the period of the run. For models with VAN in presence of
CFZ, VAN was administered as a bolus while CFZ administered as a bolus for MRSA or
as an infusion for MSSA.
Bacterial lawns from an overnight growth on TSA were suspended and added to
each model to obtain a starting inoculum of ∼106CFU/ml. Fresh medium was
continuously supplied and removed from the compartment, along with the drug, via
peristaltic pump (Masterflex; Cole-Parmer Instrument Company, Chicago, IL) at an
appropriate rate to simulate the average human antibiotic exposure concentrations,
clearances and half-lives of the antimicrobials. The antimicrobial regimens evaluated for
preliminary screening for selection of dosage most likely to produce VISA for the studies
was as follows:
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VAN 62.5 mg q 12, VAN 125 mg q 12, VAN 200 mg q 12,
VAN 250 mg q 12, VAN 500 mg q 12 for 120 hr.
Samples from each model were collected at 0, 4, 8, 24, 32, 48, 56, 72, 96, 102 and
120h in duplicate and diluted in 0.9% saline. Colony counts were determined by spiral
plating appropriate dilutions using an automatic spiral plater to enumerate the CFU per
milliliter. Colonies were counted using a laser colony counter. In addition, samples were
plated on 3x MIC VAN BHIA plate for resistance determination. If growth was observed
on the resistance plates the colonies were tested for MIC change.
In the second part of this investigation, a VAN exposure and recycling one
compartment in-vitro PK/PD model was used in the selected dosage regimen chosen
from preliminary run, for 72 hr. This procedure was incorporated to increase the rate
and reproducibility of VISA production to test our primary hypothesis. Samples from
each model were collected at 0, 4, 8, 24, 32, 48, 56, 72 hours in duplicate. The samples
were diluted, plated and incubated for 24hr on TSA before being counted. In addition, all
samples were plated on BHIA drug plate with VAN concentration 3x MIC to check for
resistance development as in previous runs. The drug plates were incubated for 48 hr.
Colonies growing on 3xMIC VAN plate (If no organisms present, colonies from TSA
plate) at T72h was re-exposed to the same regimen for additional 72-144hr to develop
VISA
To evaluate weather β-lactams could prevent the emergence of VISA Regimens
for MSSA PK/PD models included VAN at the selected dose q 12h given as a bolus+
CFZ at an increment of the MIC concentration as an infusion. If no colonies were
observed in these experiments, the concentration of CFZ is lowered until some colonies
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survived. The model sampling and plating procedure was identical for VAN alone. The
colonies obtained at T72 was re-exposed to the same regimen for additional 72-144hr
and studied for change in resistance.
Regimens for the prevention of resistance in MRSA, included VAN at the
selected dose q 12h + CFZ at a clinical therapeutic dosage regimen of 1g q 8 (since
CFZ has no activity against MRSA). If no colonies were observed, the concentration of
CFZ was lowered and dosing interval increased, until some colonies survive. The model
sampling and plating procedure was identical to VAN alone. The colonies obtained at
T72 was re-exposed to the same regimen for additional 72-144hr and studied for
change in resistance.
Resistance: The emergence of resistance was evaluated by plating 120-μl samples
from the model on plates supplemented with VAN at 3X the MIC. The plates were
examined for growth after 48 h of incubation at 35°C. Resistant colonies grown on
screening plates were evaluated by broth microdilution methods to determine the MIC. If
resistance was detected, the organism at the end of the model was characterized for its
change in MIC to other drugs.
Pharmacokinetic analysis: Pharmacokinetic samples for model run with VAN alone at
selected concentration was performed by bioassay. The organism selected was Kocuria
rhizophila (formerly Micrococcus luteus) strain ATCC 9341.
Wells were bored on agar plate with capacity of 150 μl for standard
concentrations or pharmacokinetic samples. Each standard was tested in duplicate by
placing in wells on agar plates (antibiotic medium no. 1; Difco, Detroit, MI) and
inoculated with a 0.5 McFarland standard suspension of the test organism. The samples
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were incubated for 24 hours before reading the zone of inhibition for standard and
samples. The half-life and peak concentrations were determined using the PK Analyst
software (version 1.10; MicroMath Scientific Software, Salt Lake City, UT).
3.2.5 Population Analysis Profile:
The VAN PAP/AUC was measured for isolates obtained at the end of 216 hours
or at the end of last run where any organism survived, along with the parent strain. A 2
McFarland suspension for the organism being tested containing ~10

9

CFU/ml was

prepared. Serial dilutions of the test organism were plated using automatic spiral plater
(WASP, DW Scientific, West Yorkshire, England) onto decreasing concentrations of
VAN BHI.
The VAN agar concentrations used were 0, 0.125, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5,
6, 8 and 16 mg/liter for MSSA and 0, 0.50, 1, 1.5, 2, 3, 4, 5, 6 and 8mg/liter for MRSA.
Colony growth at 48 h was measured using laser colony counter (ProtoCOL,
Synoptics limited, Frederick, MD) and graphed as log10 CFU/ml versus the VAN
concentration. Parent Strain was included in the run. The area under the curve was
calculated for each sample and compared to the mean parent AUC for each group of
PAP.
3.2.6 Serial Passage:
Serial passage in a drug free medium was carried out to check if the mutation
was stable. The organism is streaked on a drug free TSA plate and incubated at 35±2○C
for 24 hr. This is first passage. The organism obtained on the plate was re-streaked
onto TSA plate and incubated again at 35±2 ○C. This was the second passage. The
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process was repeated once more and therefore three passages were completed. The
organism obtained after each passage was analyzed for change in MIC. If the MIC
remains unchanged the mutation was considered stable.
3.2.7 Time Kill Studies:
The time kill experiments were performed in duplicate to ensure reproducibility of
the results. The 2.0ml flat bottom well trays were used for the study. The medium used
was MHB 25. Each well was inoculated to get an initial inoculum of 10 6 CFU/ml. The
antimicrobials being tested i.e. VAN and CFZ was tested at a concentration of 0.5x MIC
of each microorganism being tested. If the MIC was greater than the maximum biologic
concentration a standard dose would achieve in serum (Cmax), the Cmax value was used.
Since all S. aureus tested were MRSA and had a MIC greater than Cmax, the Cmax value
for CFZ was used.
Both of the drugs were tested alone and in combination were tested. 0.1ml
aliquot was withdrawn from each well at 0, 4, 8 and 24hr intervals. They were serially
diluted with saline and plated onto TSA plates for colony enumeration using automatic
spiral plater (WASP, DW Scientific, West Yorkshire, England). The samples were
incubated at 35±2○C before being read using a laser colony counter (ProtoCOL,
Synoptics Limited, Frederick, MD)
The time kill curves were generated by plotting mean colony counts (log10
CFU/ml) verses time. The effect of 24hr antibiotic of single agent verses combination
was compared. If there was a greater than 100-fold increase in killing with the
combination, in other words greater 2 log10CFU/ml difference between the more active
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agent and combination, the combination was considered to be synergistic.

Figure 8

represents the definition of synergy in a time kill study.

>2log10

Figure 8 Definition of synergy

The number of CFU/ml is represented on the Y axis in a log scale. The hours of
incubation are on the X-axis. The dotted line represents the growth curve in the
absence of an antibiotic. The lines labelled Drug A and Drug B are the growth curves in
the presence of an antibiotic A and antibiotic B respectively. The line labelled Drugs
A+B represents when the combination of antibiotic A and B was administered. If the
difference between the most active single drug, it this case antibiotic B, and the
combination growth curve is greater than 2 log units; the combination is synergistic.
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CHAPTER 4
RESULTS AND DISCUSSION
4.1.

Susceptibility testing
RN9120 a MSSA with dysfunctional agr II locus and JH1 an MRSA both have a

proclivity to gain resistance and become a VISA following VAN exposure. This made
them suitable candidates to study induction of resistance and prevention of resistance
development. VAN susceptibility testing for these two strains of S. aureus, RN9120 and
JH1, was performed by E-test against VAN. The results are given in Table 3
Table 3 Etest results against vancomycin

Organism

RN9120

JH1

Vancomycin MIC (mg/l)

1.5

1.5

Oxacillin MIC mg/l

0.38

48

Susceptibility testing for all other S. aureus strains (one MSSA and 11 MRSA
strains) being used for the study was performed using broth microdilution. The MIC
values for VAN, CFZ and the combination of the two drugs is given in table 4.
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Table 4 Vancomycin and Cefazolin MIC alone and in combination against S. aureus

Organism

VAN

CFZ

VAN MIC+ CFZ

RN9120

1

0.25

<0.0078

VAN MIC Fold
reduction from
baseline
>128

JH1

1

16

0.125

8

494

1

>32

0.25

4

8845

0.5

>32

0.125

4

3651

1

32

0.125

8

6387

2

>32

0.5

4

6911

2

>32

0.5

4

6837

2

>32

0.5

4

2319

8

>32

1

8

2325

8

>32

2

4

6499

1

>32

0.125

8

6256

1

>32

0.125

8

The MIC range for VAN was 0.5-8 mg/l for the organisms tested. The MSSA
isolate, RN9120, had a CFZ MIC of 0.25mg/l. The MRSA isolates had a CFZ MIC in the
range of 16 to >32mg/l.
Of note, Etest MIC for both organisms reads slightly higher that that obtained by
broth microdilution technique as shown in table 3 and table 4 respectively. It has been
described in the literature that Etests tend to give a higher value than microbroth
dilution. (59) One of the reasons for this is that a broth microdilution can read results
only in 2-fold values and not in between. Whereas, Etest is capable of obtaining
readings between the 2 values.
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The combination of VAN and CFZ produced an MIC was in the range of <0.0078
to 2. A reduction in MIC was observed anywhere between 2-fold to 5-fold. Maximum
reduction with combination use was observed with MRSA.
Combination MIC of VAN and CFZ caused reduction in MIC for all organisms
tested as compared to either agent alone. The maximum reduction was obtained with
the combination on a MSSA. This can be due to the fact that the MSSA isolate under
consideration is susceptible to both the study drugs and therefore combination results in
effects more pronounced than in organisms not susceptible to one of the drug being
tested. Over all there was a decrease in MIC to all the organisms being tested to a
combination of VAN and CFZ. The results are described in table 4.
RN9120 and JH1 were also tested for MIC against DAP, teicoplanin and oxacillin
by broth microdilution method. The MIC to these agents is given in Table 5.
Table 5 MIC (mg/l) of JH1 and RN9120 against daptomycin, teicoplanin and oxacillin.

Daptomycin

Teicoplanin

Oxacillin

RN9120

0.125

0.125

0.25

JH1

0.0625

0.25

>32

4.2.

Gradient plate serial passage
Various techniques were tried to induce resistance in S. aureus. The gradient

plate technique has been described to induce resistance in Streptococcus pyogenes
strains to β-lactams. (60) The technique was evaluated against JH1 a VSSA. The
impact of VAN exposure on the VAN MIC by this method was evaluated. The results are
summarized in Table 6
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Table 6 Vancomycin susceptibility change in gradient plate method to JH1

VAN MIC (mg/l)
ΔMIC to VAN (mg/l)
Gradient plate highest
vancomycin concentration
(mg/l)
0
1
Not applicable
8
1
0
16
1
0
24
1
0
As shown in Table 6, no change in VAN susceptibility could be obtained by this
method. Resistance could not be developed even after 3 passages on consecutively
higher VAN containing gradient plates.
4.3.

Broth serial passage
Serial passage studies have been shown to induce resistance in S. aureus,

S.epidermidis, E.faecalis, E.faecium and others to DAP in literature.(61) The technique
when tested on S. aureus RN9120 for the induction of resistance in duplicate. The
organism was inoculated in broth with VAN concentration of 0.25mg/l which is ¼ times
its MIC. After incubation at 37○C the until the organism showed visual turbidity. The
organism was then transferred to fresh BHI with elevated concentration of VAN. The
organism’s MIC was checked at every 2 mg/l increment and every 7 days. The change
in MIC as respect to time is given in Table 7.
Table 7 Change in MIC by serial passage in presence of increasing vancomycin exposure.

Vancomycin

MIC 1

2

4

10 days

19-27 days

(mg/l)
No. of days

0

It took 10 days to increase the MIC from 1 to 2 mg/l to vancomycin. A VISA with
MIC of 4 mg/l to VAN was obtained in 19-27 days of serial passage. The process took
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a very long time and showed a high variation in the two sample with reference to the
time of emergence of a VISA.
Effect of VAN exposure in presence of CFZ at ½ MIC and ¼ MIC (i.e. 0.125mg/l
and 0.0625mg/l) was evaluated in a similar fashion. The concentration of CFZ was kept
constant and the VAN concentration was increased in a fashion similar to the study with
VAN alone. When CFZ was added to the method no growth was observed at VAN
concentration of 0.75mg/l with CFZ at ½ MIC (0.125mg/l) and 1mg/l for CFZ at MIC
(0.0625mg/l). The explanation can be that the combination is bactericidal at this
concentration in static medium. Also it can be accounted to CFZ preventing the
organism from developing resistance and therefore the organism is unable to survive as
the concentration of MIC increases.
The study takes a very long time to induce a VISA and is cumbersome with
preparation of new media with increased concentration of drug at every step, thus
increasing the chances of contamination. Also the variation in the 2 samples at which
VISA emerged is high. Therefore, this method was not used for further studies.
4.4.

In vitro one-compartment PK/PD Models

4.4.1. Screening for dosage for vancomycin to induce resistance in VSSA.
The PK/PD model was used to select a dosage regimen most likely to induce a
VISA. The regimens evaluated for preliminary screening for selection of dosage for VAN
in the studies to induce low level VAN resistance in S. aureus are represented in Figure
9. The plot represents the number of colonies growing in log scale, represented on Y
axis as log10 CFU/ml verses time on the X axis in hours.
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S. aureus RN9120 (Van MIC 1) VS vancomycin at different concentration.
13
12
11
10

log10CFU/mL

9
8
7
6
5
TIME
TIME
TIME
TIME

4
3

vs
vs
vs
vs

Van 62.5 mg q 12
Van 125 mg q 12
Van 200 mg q 12
Van 250 mg q 12

2
1
0 4 8

24

32

48

56

72

80

96

104

Time (h)
Figure 9 Preliminary study for selection of vancomycin dosage to induce resistance to vancomycin in VSSA.

The results of resistance determination on colonies growing on 3x MIC VAN
BHIA plates is given in Table 8.
Table 8 MIC of S. aureus at the end of 120 hour from resistance plates

Simulated regimen of
vancomycin
62.5 mg q 12
125 mg q 12
200 mg q 12
250 mg q 12

2
2
2
2

MIC at the end of run at T 120 on resistance plate
Model A
Model B
2
2
2
2

All the models were able to increase the MIC of the organism from 1 to 2 mg/l for
vancomycin within 120 hours. Tsuji and colleagues had worked on RN9120 earlier and
successfully converted it to a VISA. (58) Also Vidaillac and colleagues worked on JH1
and transformed it into a VISA with VAN exposure.(32) In both studies the organism
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mutated to become a VISA when its growth curve was static. In other words, the growth
curve was in the mutation selection window. As shown in figure 9 only VAN 200mg q
12 regimen curve met the requirement of a potential dosage regimen to induce mutation
to generate a VISA. Thus, the dosage regimen of 200mg q 12 was selected for further
studies. The strategy of recycling was implemented to speed the process of generating
resistance.
4.4.2. Generation of VISA from VSSA
Selected S. aureus i.e. RN9120 (MSSA) and JH1(MRSA) were exposed to VAN
200 mg q 12 for 72 hours based on the data obtained from preliminary studies. The
organism obtained at the end of first run were recycled for additional exposure of 72144 hr. VAN 200mg q 12 exposure resulted in a VISA (MIC= 4mg/l) in both the S.
aureus strains under consideration within 144 hour of exposure. In addition to this JH1
was exposed to higher concentration of VAN (i.e. 500 mg q 12 for 72 hours) and
recycled for an additional 144 hour.
The graphs obtained from the study are given in figure 10 and 11 for RN9120
and JH1 respectively. The time point for change in MIC is given in Table 9 and 10 for
RN9120 and JH1 respectively.
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RN9120 (MIC 1)
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VAN 200mg q 12 for 72 +VAN 200mg q 12 for 72
VAN 200mg q 12 for 72 hr+VAN 200mg q 12 for 72 +VAN 200mg q 12 for 72

Figure 10 RN9120 VS Vancomycin 200mg q 12

Table 9 Change in MIC in PK/PD model at van 200mg q 12 exposure

Organism

RN9120

RN9120(1)

RN9120(2)

Parent

Mutant 1

Mutant 2

Vancomycin MIC

1 mg/l

2 mg/l

4 mg/l

No. of hours

0

48-56 hours

120-128 hours

216
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JH1 (VAN MIC 1) VS VAN
13
12
11
10

log10CFU/mL

9
8
7
6
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3
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144148152
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Time (h)
Van 200 mg q 12
Van 500 mg q 12

Figure 11 JH1 Vs Vancomycin 200mg q 12 and 500mg q 12

Table 10 Change in MIC in PK/PD model at van 200mg q 12 and vancomycin 500mg q 12 exposure

JH1 vs Vancomycin 200mg q 12
Organism
JH1
Parent
Vancomycin MIC
1 mg/l
No. of hours
0 hour
JH1 vs vancomycin 500mg q 12
Organism
JH1
Parent
Vancomycin MIC
1 mg/l
No. of hours
0 hour

JH1-1
Mutant 1
2 mg/l
48-56 hours

JH1-2
Mutant 2
4 mg/l
120-128 hours

JH1-1
Mutant 1
2 mg/l
>216 hours

JH1-2
Mutant 2
4 mg/l
>216 hours

216
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In both the organisms under study RN9120 and JH1 the MIC increased to
vancomycin from 1 mg/l to 2 mg/l within the first 72hours of the cycle. In other words,
first mutant of each namely RN9120(1) and JH1-1 having MIC of 2 mg/l to VAN was
generated. When the organism was recycled for the next run The MIC to both the
organisms increased to 4mg/l to VAN within 144 hours. Thus, the second mutant
RN9120(2) and JH1-2 having VAN MIC 4mg/l was generated. Even on further exposure
till 216 hours the mutant RN9120(2) remained stable.
The effect of exposing the organism at higher concentration to VAN for JH1 when
performed, no change in MIC was obtained. Therefore, it was concluded that the
organisms under study gain resistance to VAN and become a VISA when exposed to
VAN 200mg q 12 within 144 hours of suboptimal drug exposure.
4.4.3. Cefazolin in prevention of resistance in event of suboptimal VAN exposure.
In order to prove our hypothesis that CFZ is capable of preventing emergence of
VISA in the event of suboptimal dosing CFZ was added to the regimen of VAN 200mg q
12 either as infusion or as a bolus.
After the observation that the van 200mg q 12 regimen was capable of producing
a VISA from a VSSA. CFZ was added to the VAN regimen for both RN9120 and JH1 to
study its effect on prevention of resistance. For RN9120 CFZ was administered as a low
dose continuous infusion since the strain was MSSA and required a CFZ dose that
produced the desired organism effect but not enough concentration to produce
bactericidal killing on its own. This PK/PD model was evaluated at VAN regimen of
200mg q 12 with CFZ continuous infusion of CFZ at MIC the concentration of 0.25 mg/l.
The regimen produced a rapid bactericidal combination resulting in organisms below
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detection within the first 24 hours with no colonies detected at T 24h and onwards.
Therefore, we adjusted the subsequent PK/PD model run with VAN 200mg q 12 and
CFZ concentration was reduced to half (½ MIC) at 0.125mg/l. The graphs for these
models are depicted in Figure 12 and the MIC change in Table 11.

RN9120 (VAN MIC 1) VS VAN 200mg q12+ CFZ infusion
13
12
11
10

log10CFU/mL

9
8
7
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4
3
2
1
0 4 8
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72 76 80

96

104

120 128

144148152

168 176

192 200

216

Time (h)
Van 200 mg q 12+ CFZ 0.25mg infusion
Van 200 mg q 12+ CFZ 0.125mg infusion

Figure 12 RN9120 with Vancomycin 200mg q 12+ Cefazolin infusion.
Table 11 Change in MIC in PK/PD model at van 200mg q 12 and cefazolin infusion exposure

RN9120 vs Vancomycin 200mg q 12+ CFZ 0.25 mg/l infusion
Vancomycin MIC

1 mg/l

2 mg/l

4 mg/l

No. of hours

0 hour

>216 hours

>216 hours

RN9120 vs Vancomycin 200mg q 12+ CFZ 0.125 mg/l infusion
Vancomycin MIC
No. of hours

1 mg/l
0 hour

2 mg/l

4 mg/l

72 hours

>216 hours
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Since JH1 was a MRSA isolate and therefore resistant to CFZ (MIC=16mg/l) a
therapeutic dose of CFZ i.e. 1g q 8h, was administered with VAN regimen of 200mg q
12h. The PK/PD model resulted in organism colony dropping below detection limits
within 8 hours and no organisms surviving at the end of first run of 72 hours. Therefore,
the CFZ and dosing interval was increased until organisms survived at end of first
model run to be recycled. The regimens that were attempted until surviving colonies
were obtained at the end of 72 hours were as follows:


VAN 200 mg q 12h + CFZ 1 g q 8h



VAN 200 mg q 12h + CFZ 500 mg q 12h



VAN 200 mg q 12h + CFZ 250 mg q 24h



VAN 200 mg q 12h + CFZ 125 mg q 24h
On exposure to VAN 200 mg q 12h + CFZ 125 mg q 24h some organisms survived

by T72. However, no growth was observed on VAN resistance plates. The colonies
obtained at T 72h were recycled. The graph of JH1 exposed to VAN and CFZ regimen
is depicted in Figure 13. Change in MIC is given in Table 12.
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JH1 (VAN MIC 1) VS VAN200mg q 12 +CFZ
13
12
11
10

log10CFU/mL

9
8
7
6
5
4
3
2
1
0

4

8

24

32

48

56

72 76 80

96

104

120

128

144

Time (h)

Van 200 mg q 12+
Van 200 mg q 12+
Van 200 mg q 12+
Van 200 mg q 12+

CFZ 1g q 8
CFZ 500mg q 12
CFZ 250mg q 24
CFZ 125mg q 24

Figure 13 JH1 with Vancomycin 200mg q 12+ Cefazolin
Table 12 Change in MIC to vancomycin for treatment with vancomycin in presence of cefazolin.

JH1 vs Vancomycin 200mg q 12+ CFZ 125 mg q 24
Vancomycin MIC

1 mg/l

2 mg/l

4 mg/l

No. of hours

0 hour

>216 hours

>216 hours

For both the organisms RN9120 and JH1 addition of CFZ to the VAN 200mg q
12 regimen prevented the organism to become a visa. This is described in table 11 and
12. The MIC of the organism increased to 2 mg/l to VAN in case of RN9120 but did not
increase further. Therefore, CFZ in presence of VAN did have a beneficial effect in
prevention of resistance development.
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4.4.4. Pharmacokinetic analysis for model with VAN 200mg q 12h
The pharmacokinetic analysis VAN was performed by bioassay. The zone of
inhibition for standards is given in table 13.

The mean zone of inhibition vs

concentration was plotted as given in Figure 14.
Table 13 Zone of inhibition for standard concentrations

Concentration

Zone of Inhibition

(mg/l)

A

Mean

Zone

of

Inhibition

B

4

15.2

15.4

15.3

3

13.9

14.1

14

2

12.8

12.6

12.7

1

9.1

9.8

9.45

Standard plot of zone of inhibotion vs concentration
Zone of inhibition (mm)

18
16
14
12
10
8
y = 1.885x + 8.15
R² = 0.9397

6
4
2
0
0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

Concentration (mg/l)

Figure 14 Standard plot of zone of inhibition vs concentration of standards.

Thus using the equation of the standard plot the concentration of samples was
determined along with Half-life and peak concentration as shown in table 14.
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Table 14 Pharmacokinetic analysis for Van 200mg q 12

Time (h)

Mean zone of inhibition

Concentration (mg/l)

A

B

A

B

0

15.2

15.1

3.74

3.69

2

13.9

13.45

3.05

2.81

4

12.6

12.4

2.36

2.25

8

10.85

10.85

1.43

1.43

Cmax

3.78 mg/l

3.65 mg/l

T1/2

5.86 h

5.76 h

Cmax

T1/2

3.715±0.092

5.81±0.071

The pharmacokinetic study revealed that with this regimen the peak
concentration achieved was 3.7 mg/l and the half-life was 5.81. The data is given in
detail in table 14.
Furthermore, analysis of the organisms obtained at the end of the cycle after
exposure to VAN alone and exposure to VAN and CFZ was done to study difference in
the organisms obtained.
4.4.5. Population Analysis Profile
The population analysis profile demonstrated a shift in population and an
increase in Area-under-curve (AUC) with exposure to VAN 200mg q 12h as compared
to parent. In addition, CFZ prevented the population shift upon exposure to VAN. The
population analysis profile for RN9120 and JH1 are depicted in Figure 15 and 16
respectively. The change in area under curve is shown in table 15.
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Population Analysis of RN9120 initial vs Final strain with MIC 2 and 4
10

log10 CFU/ml

8

6

4

2

0

2

4

6

8

10

12

14

16

Concentration of Vancomycin
RN9120 Parent
RN9120 2MIC from model Vancomycin 200mg q12 + CFZ [0.5 x MIC (0.125mg/l)]
RN9120 4MIC from model Vancomycin 200mg q12

Figure 15 Population analysis profile for RN9120 for parent, exposed to van 200mg q 12 alone and exposed to van
200mg q 12 in presence of cefazolin.
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PAP of JH1 parent(MIC 1) vs JH1 Mutant (MIC 4) and JH1 with VAN+CFZ exposure(MIC 1)

10

Log10 CFU/mL

8

6

4

2

0
0

2

4

6

8

Concentration of Vancomycinnin BHI plates
JH1 parent
JH1 Mutant
JH1 VAN200 mg q 12+ cfz 125mg q 24 (72hr sample) .

Figure 16 Population analysis profile for JH1 for parent, exposed to van 200mg q 12 alone and exposed to van
200mg q 12 in presence of cefazolin.
Table 15 Change in MIC and AUC with exposure to vancomycin alone and vancomycin in presence of cefazolin

RN9120
Parent
MIC
to 1 mg/l
vancomycin
AUC
38.5305
JH1
MIC
to 1 mg/l
vancomycin
AUC
23.2313
The population analysis profile of

Vancomycin
200mg q 12
4 mg/l

Vancomycin 200mg q
12+ cefazolin
2 mg/l

69.5729

56.3428

4 mg/l

1 mg/l

41.1541
22.8814
parent (initial strain) vs the organisms obtained

at the end of the cycle with only VAN exposure vs exposure to VAN in presence of
cefazolin showed a distinct difference in population and area under the curves. CFZ
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when added to VAN regimen was able to reduce the shift of population to higher MIC
and reduce the area under curve for both the organisms. Figure 15 and 16 show the
shift in population for RN9120 and JH1 respectively.
CFZ addition resulted in no change in MIC for MRSA JH1 while there was some
increase in MIC to MRSA. The plausible explanation to this phenomenon would be that
the CFZ concentration in the MSSA model used was very low as compared to that used
in MRSA. Thus the amount of CFZ present was not sufficient to entirely prevent the
resistance development. Though as shown in figure 12 at higher concentration CFZ
addition to VAN regimen did not allow any organism to grow. This can also be that the
organism is unable to mutate to gain resistance and therefore is annihilated at that
concentration.
4.4.6. Serial Passage
The VISA obtained from exposure of RN9120 and JH1 to VAN namely
RN9120(2) and JH1-2 when tested for stability of mutation by serial passage, the
mutation was stable to serial passage onto antibiotic free media. There was no change
in MIC after serial passage for both RN9120(2) and JH1-2 (i.e. second mutant with MIC
4), even after 3 passages. The data is presented in table 16
Table 16 MIC on serial passage for second mutant of JH1 and RN9120

RN9120(2)
JH1-2

MIC from
resistance
plate
4 mg/l

MIC from
Passage 1

MIC from
Passage 2

MIC from
Passage 3

4 mg/l

4 mg/l

4 mg/l

4 mg/l

4 mg/l

4 mg/l

4 mg/l
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4.5.

Change in MIC to other antimicrobials.
The MIC of parent with VAN MIC 1 mg/l vs second mutant with VAN MIC 4 mg/l

was compared for various glycopeptide and lipopeptide and β-lactam to check for cross
resistance. The agents used in the study include VAN, DAP, Teicoplanin, CFZ and
oxacillin. The MIC are given in table 17.
Table 17 MIC of parent and mutant.

VAN (mg/l)

DAP (mg/l)

TEI (mg/l)

CFZ (mg/l)

OXA (mg/l)

RN9120

1

0.125

0.125

0.25

0.25

RN9120(2)

4

1

4

0.25

0.25

JH1

1

0.0625

0.25

16

>32

JH1-2

4

0.5

8

1

2

An interesting pattern observed was that as the VAN MIC increased the MIC to
other glycopeptide and lipopeptide also increased in case of both organisms. This
proves the potential of development of cross resistance by prior VAN exposure. In
addition to this the MIC for beta lactams in case of MRSA decreased as the organism
became more resistant to VAN. Thus demonstrating the seesaw effect in accordance to
the literature.(42) The MIC of beta lactam in MSSA remained unchanged. The tentative
explanation is that VAN interferes with the production of folding of PBP2A present only
in MRSA, either by deleting the mecA gene or by disrupting PrsA, a protein responsible
for folding in the region of PBP 2A. This increases the susceptibility of the organism to
β-lactams.
4.6.

Time kill studies
The green cross is the Growth control, blue closed circle is VAN alone, pink

closed square is CFZ alone and red open square is the combination drug treatment.
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Figure 17-21 represent time kill for MRSA. Figure 22 and Figure 23 denote hVISA while
Figure 24 and 25 are plots of time kill curve of VISA. Linezolid (LNZ) resistant strain
time kill curves is shown in figure 26 and 27.

TIME KILL 494

12
11
10

log 10CFU/mL

9
8
7
6
5
4
GC
Van
CFZ
VAN+CFZ

3
2
1
0

4

8

24

Time (h)

Figure 17 MRSA 494 Time kill plot
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TIME KILL 3651
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Figure 18 MRSA 3651 Time kill plot

TIME KILL 6387
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Figure 19 MRSA 6387 Time kill plot
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TIME KILL 8845
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Figure 20 MRSA 8845 Time kill plot

TIME KILL JH1
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Figure 21 MRSA JH1 Time kill plot
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TIME KILL 6911
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Figure 22 hVISA 6911 Time kill plot

TIME KILL 6837
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TIME KILL 2319
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Figure 24 VISA 2319 Time kill plot

TIME KILL 2325
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Figure 25 VISA 2325 Time kill plot
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TIME KILL 6499

12
11
10

log 10CFU/mL

9
8
7
6
5
4
6499
6499
6499
6499

3
2

GC
Van
CFZ
VAN+CFZ

1
0

4

8

24

Time (h)

Figure 26 LZD-R 6499 Time kill plot
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Figure 27 LZD-R 6256 Time kill plot
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The time kill studies on various phenotypes of MRSA shown above, corroborate
our data of the advantage of using CFZ in combination to VAN. In all 11 strains studied
for time kill study, the addition of CFZ to VAN resulted in synergy for all strains tested
regardless of varying susceptibility patterns to VAN or LNZ. The strain 2325 was the
only strain which showed less pronounced effect. This may be strain specific. The
organism was a VISA with MIC to VAN 8. The synergy was seen even on this strain
though bactericidal activity of the combination was lower.
DISCUSSION:
In this study we validated that suboptimal VAN dosing in S. aureus leads to VISA
for both MSSA (RN9120) and MRSA (JH1).
Previous experiments by Celine and colleagues have shown that over a period of
30 and 60 days of VAN dosing of 500 mg q 12h and 1g q 12 h against JH1 results in a
VISA. Several mutations were reported namely yvqF (H164R), rpoB (D471Y, A473S,
A477S, E478D), rpoC (E854A) and SA1129 (D296Y) associated with VISA. In addition
to this phenotypic changes associated with VISA was observed, specifically reduced
susceptibility to VAN and thickening of cell wall. (56)
In addition to MRSA, VAN reduced susceptibility had also been reported for
MSSA in clinical strains.(62) B. Tsuji and his colleagues

proved that MSSA with

dysfunctional AGR group have a proclivity towards developing resistance to VAN on
suboptimal exposure.(58)
Using our method of recycling at suboptimal VAN concentration we were able to
generate VISA faster and more reproducibly as compared to other methods including
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gradient plate method and broth serial passage methods. In both MSSA and MRSA we
were able to generate a VISA within 144 h.
Previous studies have evaluated combination of VAN and a variety of betalactam for synergy. VAN and Nafcillin have been shown to be synergistic in more than
90% strains in time kill studies with overall increase in magnitude of activity in PK/PD
models. (47)
Similarly, many previous studies have reported synergy with VAN with betalactams such as cefepime, cefpirome, carbapenam, cefotaxime and many others. (63,
64) CFZ in combination to VAN had been evaluated for synergy against S. epidermidis
and had been found effective in about 40% of the cases.(65) There is very little
information about the combination of VAN and CFZ against S. aureus. Rochon and his
colleagues had tested 26 different beta-lactams in combination with VAN against 32
MRSA. They found in their studies that CFZ was one of the most effective beta-lactams
in combination with VAN. (45)

In addition to this

CFZ had fewer side effects as

compared to drugs like nafcillin.(54) These advantages of CFZ paved the way for use of
CFZ in our study.
Combination MIC of VAN and CFZ revealed in accordance to the studies
performed by Rochon and his colleagues, that the combination caused reduction in MIC
for all organisms tested as compared to either drug alone.(45)
Some studies have evaluated the pharmacodynamic of VAN in combination of
beta-lactam in PK/PD models. The combination has been reported to kill faster than
single agent in MRSA, VISA and hVISA.(46)
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The studies done by previous researchers concentrate on the combination of
VAN and CFZ being synergistic.

The combination demonstrated to have improved

bactericidal activity against an MRSA and hVISA strain in an in vitro studies. However,
there is little to no data examining the impact of beta-lactam exposure including CFZ on
the prevention of generation of VISA. In fact, CFZ even at suboptimal doses of 125mg q
24 for JH1 and 0.125mg/l infusion for RN9120 was effective in preventing the
generation of a VISA in both phenotypes.
Clinical investigations have demonstrated that suboptimal VAN exposure can
lead to VISA and treatment failure.(66) The acquisition of VISA is important since these
strains are often cross resistant to DAP which is one of the primary alternatives to VAN
therapy especially in the face of VAN failure. (67) In our study we found that increase in
VAN resistance resulted in increase in MIC to other glycopeptide teicoplanin and
lipopeptide DAP. In addition, our data would suggest that application of a beta-lactam
like CFZ and VAN as initial therapy may prevent the emergence of VISA on VAN
therapy. This has potential important clinical implications since the VAN failure often
leads to subsequent failure with alternative (salvage) antibiotics such as DAP. The
prevention of resistance by using a combination of VAN and CFZ will be beneficial to
patient.
In addition, the choice of beta-lactam is important as safety, the ease of
administration, cost are important factors in selecting antibiotic therapy. While there is
data to suggest that alternative beta-lactams such as nafcillin may demonstrate synergy
against S. aureus including MRSA, CFZ has been shown to be a safer alternative to
nafcillin and can be more easily administered (q 4-6 hours for nafcillin versus q 8-12
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hours for CFZ). (54, 68) Berti and his colleagues in a study showed that beta-lactam
antibiotics targeting PBP1 had enhanced DAP activity against MRSA.(53) PBP1 is a
membrane protein required with cell wall synthesis. CFZ had affinity to PBP1 making it
a potential antibiotic for synergy. In addition to this low cost of therapy made CFZ an
ideal candidate for the study.
In the second part of our study synergy was observed in various phenotypes of
MRSA including VISA, hVISA and LNZ-R strains. This information is useful clinically
and makes it a potential candidate for treatment of difficult MRSA.
Limitations of the research:
Only one organism of each phenotype was used for the study. To verify that the
combination of VAN and CFZ is effective in preventing resistance additional organisms
from MSSA and MRSA should be explored.
Also VAN and CFZ combination was studied for a relatively short period of time.
In clinical setting a patient may receive the antibiotics for a longer duration of time and
therefore study should be carried out for a longer period of time to ensure it prevents
resistance.
Only one beta-lactam (CFZ) was explored in our study. Other beta-lactams like
Nafcillin, cefepine, ertamenam, meropenem need to be explored with VAN to study their
potential in prevention of resistance.
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CHAPTER 5
CONCLUSION
From the studies it can be concluded that sub-therapeutic exposure to VAN
induces resistance in both MSSA (RN9120) and MRSA(JH1) isolates and the addition
of CFZ to the regimen prevented of emergence of VISA for both MSSA and MRSA.
A positive correlation was established between the MIC changes for VAN and
other glycopeptides/lipopeptides. Thus indicating a potential of developing crossresistance to other drugs as the organism develops resistance to VAN.
A negative correlation was observed between VAN MIC and β-lactam (CFZ) in
case of MRSA indicating VAN may interfere with the organism’s mechanism to gain βlactam resistance. In other words, it interferes with PBP2A by some mechanism making
the organism more susceptible to β-lactam.
The time kill study corroborates the data of advantage of using VAN in
combination to CFZ.
Additional studies on a wider range of isolates, more antibiotic combinations
along with experiments on animal models will further validate the utility of this antibiotic
combination for clinical use.
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ABSTRACT
IMPACT OF CEFAZOLIN CO-ADMINISTRATION WITH VANCOMYCIN TO REDUCE
DEVELOPMENT OF VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS
by
NIVEDITA B SINGH
August 2016
Advisor: Dr. Michael J. Rybak
Major: Pharmaceutical Sciences
Degree: Master of Science
Objective: Development of resistance in S. aureus has been a big concern in the
treatment of infections caused by the organism. The line of therapy used today has a
disadvantage of slowly developing cross-resistance for antibiotics such as DAP
secondary to prior VAN exposure. Therefore, alternative therapy is needed to prevent
the emergence of VAN resistance and cross-resistance to other antibiotics. The primary
aim of this experiment is first: to prove that sub-optimal VAN exposure in S. aureus will
lead to development of VISA. Secondly, VAN in combination with cefazolin (CFZ) will
prevent the development of VISA, regardless of sub-therapeutic vancomycin exposure.
In addition to this we will evaluate if the combination of vancomycin and CFZ is
synergistic against various phenotypes of MRSA.
Methods: Two strains of S. aureus, one MSSA (RN9120) and one MRSA (JH1)
having a proclivity to gain resistance to vancomycin was used to induce resistance. The
organisms were exposed to subtherapeautic VAN concentrations in a 1-compartment
pharmacokinetic/pharmacodynamic (PK/PD) model, simulating human PK of VAN 200
mg q 12h over 72 h to induce resistance. At 72h, organisms recovered from the model
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were re-exposed to the same VAN regimen for an additional 72-144 h exposure to
generate VISA. The same experiment was repeated with continuous infusion of CFZ for
MSSA and bolus administration for MRSA. Changes in MIC were evaluated at the end
of each 72 h exposure. A population analysis profile (PAP) was performed to evaluate
for shifts in population susceptibility. All PK/PD models were completed in duplicate to
ensure reproducibility.
In addition to this Time kill experiments were carried out on 10 isolates of MRSA
with various phenotypes including MRSA, VISA, hVISA and LNZR strains.
Results: VAN MIC of RN 9120 and JH1 increased to 4 mg/L as soon as 144h
under sub-therapeutic VAN exposure. When CFZ was concomitantly administered, VAN
MIC increased to 2 mg/L at 72h. However, no further increase in MIC was noted up to
216h of sub-therapeutic VAN administration. The MIC for MRSA remained unchanged
when combination of VAN and CFZ was evaluated. PAP revealed a shift in the overall
population towards non-susceptibility with VAN alone. CFZ when added to VAN caused
a lesser shift in MSSA and no shift in MRSA.
Time kill studies showed synergy in all 10 MRSA under study.
Conclusion: The addition of low concentration of CFZ appears to prevent
emergence of VISA under sub-therapeutic exposure to VAN. The time kill study
corroborates the data of advantage of using VAN in combination to CFZ. Additional
studies on a wider range of isolates, more antibiotic combinations along with
experiments on animal models will further validate the utility of this antibiotic
combination for clinical use.
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